TG Therapeutics Inc (NASDAQ: TGTX) has reported earnings for its fourth fiscal quarter (ending December 31) of $0.16 versus a loss $-0.10 for the same period a year ago — a decline of -260%. For the latest four quarters through December 31, E.P.S. were $0.16 compared to $0.09 a year ago — an increase of 78%.
Recent Price Action
On 3/3/25, TG Therapeutics Inc (NASDAQ: TGTX) stock enjoyed a major increase of 14.4%, closing at $34.42. Moreover, exceptionally high trading volume at 581% of normal accompanied the advance. The stock has risen 11.5% during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
TG Therapeutics has a current Value Trend Rating of A (Highest Rating). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. TG Therapeutics has a very high Power Rating of 89 and a very high Appreciation Score of 92, producing the Highest Value Trend Rating.
Rating Review
In light of this new information and very positive price change we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment